Supplement enforcement in 2026: FDA, FTC and ASA data

On 20 October 2026 the FDA finalised the identity and safety sections of its guidance on new dietary ingredient (NDI) notifications. Alongside that, we counted what regulators actually acted on this year. From 1 January to 22 October 2026, the FDA, the US Federal Trade Commission and the UK Advertising Standards Authority took 39 formal actions against supplement companies.

Key finding: 11 of the FDA’s 18 supplement warning letters in 2026 cited disease or drug claims, on their own or alongside other violations. Claims, not just factories, are what gets companies letters.

The FDA’s 18 supplement warning letters, by violation

One of the two new-ingredient letters went to a product marketed as a “GLP-1 biomimetic”: the GLP-1 trend is reaching supplement shelves.

The FTC: claims about mental health and children’s height

The FTC’s four supplement actions this year involved two companies. TruHeight was charged over height-growth claims for supplements marketed to children and teens (complaint and proposed settlement in April, final order in July). Amare Global was charged over claims that its supplements treat depression, anxiety and ADHD (complaint 2 June), and the FTC also moved to hold it in contempt of an earlier order (12 June).

The UK: 17 upheld ASA rulings

The ASA upheld 17 rulings against supplement ads in 2026. They include a 25 March batch of five rulings on women’s hormone supplements making menopause and PCOS claims, and products claiming GLP-1-like effects. In October the ASA also reported that only a small share of ads for supplements aimed at ADHD and autism, and for prostate supplements, complied with the rules.

What changes with the NDI guidance

The final sections explain what identity and safety information the FDA expects in an NDI notification. Two of this year’s letters were about new ingredients where the FDA judged the safety evidence inadequate, in one case after objecting to the company’s notifications. Brands launching products with new ingredients now have clearer expectations to meet.

What this means for supplement brands’ PR

A claim that would get a warning letter on a label will also sink a press release: health journalists check claims against what regulators allow. Our wellness and beauty PR work starts from claims that hold up, and our guide to PR for supplement brands covers how to get coverage without them.

This is a summary of public enforcement records, not legal advice.

How we’re pitching this

This data was built to be pitched. Here is how we’re taking it to journalists, as an example of how we run data-led PR for supplement and wellness brands.

The list is 9 writers: supplement, food and beverage trade news, FDA and health-policy reporters, and health and nutrition writers who covered supplement safety or evidence in recent weeks. Six pitches build on a specific recent story; three lead with the data.

• One writer per outlet, chosen because they covered this topic in the last 90 days. Every pitch opens with that writer's own recent story, so it builds on their work rather than arriving cold.
• Verified addresses only. No guessed emails, and catch-all addresses are held back for a manual check.
• Short, with one ask. 116–163 words, three numbers, a one-line method, links to this page and the CSV, and an offer of the fuller figures. We don't ask for a link.
• One follow-up a few days later, carrying a new number from the same data rather than a nudge.

Here is one of the pitches, with the journalist’s details removed:

Subject: 11 of 18 FDA Supplement Warning Letters in 2026 Cited Disease Claims

Hi [name],

Your [date] story covered a regulator acting against a GLP-1 supplement over misleading claims. US and UK regulators have been dealing with the same trend: we counted 39 formal actions against supplement companies in 2026 across the FDA, FTC and UK Advertising Standards Authority.

• 11 of the FDA’s 18 supplement warning letters this year cited disease or drug claims
• One FDA letter went to a product marketed as a “GLP-1 biomimetic”, over the safety of a new ingredient
• The UK watchdog upheld 17 rulings against supplement ads, including products claiming GLP-1-like effects

HealthSpark PR classified every FDA warning letter dated 1 January to 22 October 2026, plus FTC actions and ASA rulings, with a source link for each.

Write-up and data (CSV): [links]

Happy to send the letters broken down by violation type.

The follow-up adds one new figure: the FTC’s four supplement actions this year involved just two companies, one over height-growth claims for children and one over claims its products treat depression, anxiety and ADHD.

We’ll add what came back once the replies are in. If you’re a journalist and want the underlying figures, get in touch.

Method

• FDA: all 474 warning letters dated 1 Jan – 22 Oct 2026, classified from the letter text. Letters FDA filed under drugs or food are included where they concern products marketed as dietary supplements.
• FTC: every 2026 FTC press release, plus the case pages for candidate actions. Multi-level marketing cases about earnings claims are excluded.
• ASA: all formal rulings published 1 Jan – 22 Oct 2026, filtered by topic and checked by hand.